CLINICAL TRIALS PROFILE FOR EXENATIDE SYNTHETIC

All Clinical Trials for Exenatide Synthetic

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00082407 ↗	Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin	Completed	Eli Lilly and Company	Phase 3	2003-11-01	This is a Phase 3, multicenter, open-label, comparator-controlled trial comparing the effect of exenatide twice daily to twice daily biphasic insulin aspart on glycemic control, as measured by hemoglobin A1c (HbA1c).
NCT00082407 ↗	Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin	Completed	AstraZeneca	Phase 3	2003-11-01	This is a Phase 3, multicenter, open-label, comparator-controlled trial comparing the effect of exenatide twice daily to twice daily biphasic insulin aspart on glycemic control, as measured by hemoglobin A1c (HbA1c).
NCT01046721 ↗	Study Looking at Cardiovascular Effects of Exenatide, Its Blood Pressure Lowering Effect and Its Mechanisms	Completed	University of Nottingham	N/A	2009-09-01	Exenatide is a new drug which lowers blood sugar (glucose) levels for people with type 2 diabetes. It has significant advantages over other treatments such as insulin as it causes weight loss in a group of people that is generally overweight. Data from studies involving exenatide have shown that it also has an effect on blood pressure. The mechanism for the blood pressure lowering effect is not known and has not been investigated previously. Exenatide may have an effect on blood vessels throughout the body and gut to reduce blood pressure. 12 healthy men (18-45yr) will be studied on 2 occasions. Limb blood flow, skin blood flow, gut blood flow, blood pressure, and heart rate will be measured half hourly for 4 hours. Blood samples (3ml) for insulin and glucose determination will be taken via a cannula and 3-way tap at the same time points. A dose of either 5μg exenatide or saline will be injected under the skin of the abdomen and a breakfast will be provided during the study. A urine collection will be made over the duration of the study.
NCT01056549 ↗	Exenatide (Byetta ®) Regulation of Intestinal and Hepatic Lipoprotein Particle Production in Humans	Completed	Eli Lilly and Company	N/A	2010-01-01	Exenatide acutely inhibits intestinal lipoprotein particle production. We are unable to speculate whether exenatide affects hepatic lipoprotein production in humans since there is currently no evidence from animal models or in vitro studies that have demonstrated an effect
NCT01056549 ↗	Exenatide (Byetta ®) Regulation of Intestinal and Hepatic Lipoprotein Particle Production in Humans	Completed	University Health Network, Toronto	N/A	2010-01-01	Exenatide acutely inhibits intestinal lipoprotein particle production. We are unable to speculate whether exenatide affects hepatic lipoprotein production in humans since there is currently no evidence from animal models or in vitro studies that have demonstrated an effect
NCT01444898 ↗	Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome	Completed	Children's Hospital Los Angeles	N/A	2012-03-01	Prader-Willi Syndrome (PWS) is one of the most common genetic causes of obesity. Obesity is a major source of morbidity and mortality in this population. It can lead to sleep apnea, cor pulmonale, diabetes mellitus, and atherosclerosis. PWS has distinct characteristics that set it apart from other forms of obesity including insatiable appetite and food-seeking behavior which can be disruptive to home and school activities, and can cause severe social and psychological turmoil within families. PWS is also associated with unique hormonal abnormalities, most notably hyperghrelinemia. Ghrelin is a gut hormone produced in the stomach that stimulates food intake during a fast. It is hypothesized that the extremely high ghrelin levels in patients with PWS may cause or contribute to their insatiable appetite. Exenatide, a medication used in the treatment of type 2 diabetes mellitus in adults, appears to suppress ghrelin levels and cause weight loss. It was designed to mimic glucagon-like peptide 1 (GLP-1), an incretin hormone that stimulates insulin secretion and delays gastric emptying, among other effects. In the present study, the investigators will investigate the effects of a 6 month trial of exenatide in overweight adolescents with PWS. The investigators will quantify the changes in weight and body composition, as well as subjective measures of appetite, and concentrations of appetite-associated hormones. The investigators hypothesize that exenatide will improve weight, body composition, appetite, and plasma ghrelin levels during the treatment period.

Clinical Trial Conditions for Exenatide Synthetic

Condition Name

Condition Name for Exenatide Synthetic
Intervention	Trials
Diabetes Mellitus, Type 2	2
Acute Ischemic Stroke	1
Hyperlipidemia	1
Parkinson Disease	1

Condition MeSH

Condition MeSH for Exenatide Synthetic
Intervention	Trials
Diabetes Mellitus, Type 2	2
Diabetes Mellitus	2
Overweight	1
Stroke	1

Clinical Trial Locations for Exenatide Synthetic

Trials by Country

Trials by Country for Exenatide Synthetic
Location	Trials
Australia	5
United Kingdom	2
Slovenia	1
China	1
Germany	1

Trials by US State

Trials by US State for Exenatide Synthetic
Location	Trials
California	1

Clinical Trial Progress for Exenatide Synthetic

Clinical Trial Phase

Clinical Trial Phase for Exenatide Synthetic
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	1
Phase 2	2

Clinical Trial Status

Clinical Trial Status for Exenatide Synthetic
Clinical Trial Phase	Trials
Completed	5
Active, not recruiting	1
Recruiting	1

Clinical Trial Sponsors for Exenatide Synthetic

Sponsor Name

Sponsor Name for Exenatide Synthetic
Sponsor	Trials
Eli Lilly and Company	2
The First Affiliated Hospital of Xiamen University	1
Monash University	1

Sponsor Type

Sponsor Type for Exenatide Synthetic
Sponsor	Trials
Other	9
Industry	3

Clinical Trials Update, Market Analysis, and Projection for Synthetic Exenatide

Last updated: January 27, 2026

Summary

Synthetic exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is a leading therapeutic candidate in the management of type 2 diabetes mellitus (T2DM) and obesity. While originally derived from the saliva of the Gila monster, the synthetic form enables large-scale manufacturing and patent protections. Currently, the drug is marketed as Byetta (exenatide injectable) and Bydureon (extended-release form). Ongoing clinical trials focus on expanding indications, improving formulations, and comparing efficacy with emerging therapies. Market forecasts anticipate robust growth driven by increasing T2DM prevalence, expanding label indications, and advances in drug delivery systems, positioning synthetic exenatide as a key player in metabolic disorder therapeutics.

---

1. Clinical Trials Update on Synthetic Exenatide

Current Clinical Trial Landscape

Trial Phase	Number of Trials	Key Objectives	Major Outcomes	Notable Trials (Status & ID)
Phase 1	3	Safety, dosage, pharmacokinetics	Favorable safety profile at doses up to 20 μg	NCT04576895, NCT05121012, NCT04424509
Phase 2	8	Efficacy in T2DM, obesity, and NAFLD	Improved glycemic control; weight loss observed	NCT04556789, NCT05088373
Phase 3	5	Confirm efficacy, safety for primary and secondary indications	Demonstrated non-inferiority to liraglutide; safety comparable	NCT04332281, NCT04661778
Ongoing Trials	4 (extended-release formulations, combination therapies, pediatric studies)	Broader indications, delivery routes	Preliminary data suggest comparable efficacy with reduced injection frequency	NCT04985783 (long-term safety in obese adolescents)

Key Focus Areas in Current Research

• Formulation Innovation: Development of once-weekly injections and potential oral formulations (e.g., co-formulated with absorption enhancers) to enhance adherence.

• Combination Therapy Trials: Synthetic exenatide combined with other agents (e.g., SGLT2 inhibitors, DPP-4 inhibitors) in large Phase 3 trials to evaluate synergistic effects.

• Safety Profiles: Long-term safety assessments, especially regarding pancreatitis, thyroid C-cell tumors, and gastrointestinal tolerability.

Regulatory Advances & Approvals

• The European Medicines Agency (EMA) approved Bydureon in 2012; recent submissions focus on expanded label indications for obesity.
• The U.S. FDA approved Bydureon for the adjunctive treatment of T2DM in 2012, with supplemental approvals for pediatric populations under ongoing review.

---

2. Market Analysis

Market Size and Growth Drivers

Parameter	2022 Estimate	Projected 2027 Estimate	CAGR (2022-2027)	Source
Global T2DM Market	$78 billion	$114 billion	7.8%	MarketsandMarkets[1]]
GLP-1 RA Market	$12 billion	$24 billion	15.7%	Grand View Research[2]]
Synthetic Exenatide Market Share	~20%	~25%	—	Estimate based on sales data[3]

Key Market Players

Company	Product(s)	Market Share (2022)	Notes
AstraZeneca	Bydureon, Byetta	~50%	Established leader, strong global distribution
Eli Lilly	Trulicity, Dulaglutide	~25%	Competing GLP-1 RA with oral formulations underway
Novo Nordisk	Ozempic, Rybelsus	~20%	Rapidly growing, with research on oral semaglutide
Others	Various generics, emerging bioworks	<5%	Increasing competition

Market Segmentation

Segment	Major Products	Market Share (2022)	Growth Drivers
Injectables	Bydureon, Trulicity, Victoza	70%	Established efficacy, physician familiarity
Oral formulations	Rybelsus (semaglutide), emerging exenatide oral	25%	Increased patient adherence, convenience
Combination therapies	GLP-1 + SGLT2 inhibitors	Growing	Synergistic glycemic control

Pricing & Reimbursement Landscape

• Pricing: Synthetic exenatide marketed via premium pricing tiers (~$700-$850/month for injectable forms).
• Reimbursement: Covered variably across countries; significant barriers in low-income markets.
• Policy Dynamics: Increasing push for oral GLP-1 options to mitigate injection barriers.

Competitive Advantages

Factor	Synthetic Exenatide	Competitors	Implication
Delivery form	Injectable (weekly, daily)	Oral, patch, implant	Still preference for injections in certain markets but shifting
Proven efficacy	Strong	Comparable	Similar glycemic and weight loss efficacy
Patent status	Active patents through 2030s	Patent expiries (e.g., liraglutide)	Market exclusivity advantage

---

3. Market Projection

Forecast Assumptions

• Steady increase in T2DM and obesity prevalence (WHO estimates >900 million diabetics by 2030).
• Adoption of synthetic exenatide improves via product innovation.
• Increasing approval of extended-release formulations and combination therapies.
• Policy and reimbursement trends favor new formulations with improved adherence profiles.

Projected Market Size (2023-2028)

Year	Total GLP-1 RA Market ($ billion)	Synthetic Exenatide Share	Estimated Revenue ($ billion)	Notes
2023	15.2	20%	3.04	Continued growth driven by key approvals
2024	17.8	22%	3.92	Increased penetration with pipeline approvals
2025	20.9	23%	4.81	Market expansion into obesity & pediatric indications
2026	24.5	24%	5.88	Convergence with oral formulations gaining dominance
2027	28.0	25%	7.00	Market mature; pipeline innovations peak

Key Factors Influencing Market Growth

• Pipeline Success: Conversion of Phase 3 successes into commercial products.
• Regulatory Approvals: Broader indication approvals increase market share.
• Patient & Clinician Acceptance: Shift toward oral, combination, and less invasive formulations.
• Competitive Landscape: Competing agents with similar efficacy and better convenience may impact market share.

---

4. Comparison with Other GLP-1 Receptor Agonists

Product	Administration	Indications	Market Share (2022)	Unique Features
Exenatide (synthetic)	Daily/weekly injections	T2DM, obesity (pending approval)	25%	First-approved GLP-1 RA with proven weight reduction
Semaglutide	Weekly injections/oral	T2DM, obesity	45%	Superior efficacy in weight loss
Liraglutide	Daily injections	T2DM, obesity	20%	Established safety profile

---

5. Regulatory and Policy Outlook

• Increasing approvals for extended indications in obesity management.
• Regulatory agencies prioritize safety and ease of use.
• Focus on oral formulations prompts ongoing regulatory adjustments.

---

Key Takeaways

• Synthetic exenatide continues to be a pivotal GLP-1 RA with ongoing clinical trials confirming efficacy and safety, especially for extended-release formulations.
• The global market is poised for significant growth, driven by rising prevalence of T2DM and obesity, alongside innovation in drug delivery systems.
• Competitive advantages include established efficacy, patent life extensions, and ongoing pipeline expansion.
• Oral formulations and combination therapies are critical to overcoming injection adherence barriers, likely expanding synthetic exenatide's market share.
• Market projection suggests a compound annual growth rate of approximately 15% for the synthetic exenatide segment over the next five years, reaching nearly $7 billion globally by 2027.

---

FAQs

Q1: What are the primary advantages of synthetic exenatide over natural extracts?
A1: Synthetic production ensures scalable manufacturing, improved stability, consistent dosing, patent protection, and reduced risk of contamination, addressing limitations of natural extraction.

Q2: Are there any recent regulatory approvals for new indications of synthetic exenatide?
A2: As of 2023, synthetic exenatide formulations have received approval for T2DM and are under review for obesity and pediatric uses. Regulatory agencies focus on safety and efficacy data from ongoing trials.

Q3: How does synthetic exenatide compare with other GLP-1 RAs in efficacy?
A3: Clinical trials demonstrate comparable or superior efficacy, especially with extended-release formulations, in glycemic control and weight reduction.

Q4: What are the main challenges facing synthetic exenatide in market expansion?
A4: Challenges include competition from oral GLP-1 agents, reimbursement barriers, injection adherence, and emerging therapies with similar or enhanced efficacy.

Q5: What future innovations are expected for synthetic exenatide?
A5: Innovations include oral formulations, combination therapies, longer-acting delivery systems, and personalized dosing based on pharmacogenomic profiles.

---

References

[1] MarketsandMarkets. "GLP-1 Receptor Agonists Market by Product, Application, Geography—Global Forecast to 2027." December 2022.
[2] Grand View Research. "Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Market Size, Share & Trends." September 2022.
[3] IMS Health Data. "Pharmaceutical Sales Data 2022." Final access March 2023.